|
|
Volumn 49, Issue 3, 2010, Pages 395-396
|
|
Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
CAPECITABINE;
FLUOROURACIL;
FOLINIC ACID;
IRINOTECAN;
OXALIPLATIN;
BLEEDING;
CANCER COMBINATION CHEMOTHERAPY;
CANCER PATIENT;
CANCER SURVIVAL;
COLORECTAL CANCER;
DIGESTIVE SYSTEM PERFORATION;
DRUG INFUSION;
DRUG SAFETY;
DRUG WITHDRAWAL;
HUMAN;
HYPERTENSION;
LETTER;
MAJOR CLINICAL STUDY;
METASTATIC COLORECTAL CANCER;
MULTIPLE CYCLE TREATMENT;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
PROTEINURIA;
THERAPY EFFECT;
THROMBOEMBOLISM;
TREATMENT DURATION;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
VENOUS THROMBOEMBOLISM;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CAMPTOTHECIN;
COLORECTAL NEOPLASMS;
DEOXYCYTIDINE;
DRUG ADMINISTRATION SCHEDULE;
FEASIBILITY STUDIES;
FLUOROURACIL;
HUMANS;
INFUSIONS, INTRAVENOUS;
LEUCOVORIN;
ORGANOPLATINUM COMPOUNDS;
RETROSPECTIVE STUDIES;
SURVIVAL ANALYSIS;
TIME FACTORS;
TREATMENT OUTCOME;
|
|
EID: 77951262917
PISSN: 0284186X
EISSN: 1651226X
Source Type: Journal
DOI: 10.3109/02841860903428184 Document Type: Letter |
|
Times cited : (6)
|
|
References (5)
|
